Evidence map›Paper›PMID 39286625›Full record

ArticleEJVES vascular forum2024

Midterm Outcomes With the Nellix Endograft Alone or With Chimneys.

Salomé Kuntz, Céline Deslarzes, Alexandre Than Vinh Nguyen, Alban Longchamp, Rosalinda D'Amico, Justine Longchamp, Anne Lejay, Nabil Chakfé, Sébastien Déglise

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJVES vascular forum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Salomé KuntzDepartment of Vascular Surgery and Kidney Transplantation, University of Strasbourg, France.
Céline DeslarzesDepartment of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland.
Alexandre Than Vinh NguyenDepartment of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland.
Alban LongchampDepartment of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland.
Rosalinda D'AmicoDepartment of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland.
Justine LongchampDepartment of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland.
Anne LejayDepartment of Vascular Surgery and Kidney Transplantation, University of Strasbourg, France.
Nabil ChakféDepartment of Vascular Surgery and Kidney Transplantation, University of Strasbourg, France.
Sébastien DégliseDepartment of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Endovascular aneurysm sealing (EVAS) appeared to be an innovative alternative to conventional endovascular abdominal aortic aneurysm repair. However, high rates of midterm failure of EVAS led to withdrawal of the device from the market. The study aim was to report midterm outcomes of patients treated with EVAS alone or associated with chimneys (Ch-EVAS) and the management of their complications. Methods: In this single centre study, all consecutive Nellix implants between 2013 and 2016 were included. The primary endpoint was device failure: (1) a triad of caudal migration of the Nellix stents >5 mm, separation of the endobags (>5 mm), and sac enlargement (>5 mm), with or without visible endoleak, (2) secondary aneurysm rupture, (3) surgical explant of the graft, or (4) any intervention for a type I endoleak. Overall mortality, aneurysm related mortality, and re-intervention rates were analysed. Results: Fifty patients (male Conclusion: The midterm outcome of EVAS is poor. All patients who underwent EVAS implantation must be informed and should undergo frequent surveillance. Open repair and device explantation should be considered as the primary treatment.

Indexed as

Abdominal aortic aneurysmEndoleakEndovascular Aneurysm SealingEVASNellix

Identifiers

PMID39286625
PMCPMC11404053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.